ESPR FY 2022 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$577M

FY 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$75M-3.8% YoY

Gross Profit

$49M64.3% margin

Operating Income

-$180M-237.8% margin

Net Income

-$234M-309.6% margin

EPS (Diluted)

$-4.33

Cash Flow

Operating Cash Flow

-$175M

Free Cash Flow

-$175M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$248M

Total Liabilities

$572M

Stockholders' Equity

-$324M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$78M	-3.8%
Gross Profit	$49M	$64M	-24.5%
Operating Income	-$180M	-$227M	+20.8%
Net Income	-$234M	-$269M	+13.2%